300
Participants
Start Date
November 20, 2015
Primary Completion Date
April 2, 2018
Study Completion Date
December 24, 2019
Apixaban
Given PO
Dalteparin
Given SC
Questionnaire Administration
Ancillary studies
Guthrie Medical Group PC-Robert Packer Hospital, Sayre
FirstHealth of the Carolinas-Moore Regional Hosiptal, Pinehurst
Columbus NCI Community Oncology Research Program, Columbus
Toledo Clinic Cancer Centers-Toledo, Toledo
Cancer Research Consortium of West Michigan NCORP, Grand Rapids
Siouxland Regional Cancer Center, Sioux City
University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Metro Minnesota Community Oncology Research Consortium, Saint Louis Park
Mayo Clinic, Rochester
Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud
Rapid City Regional Hospital, Rapid City
NorthShore University HealthSystem-Evanston Hospital, Evanston
Illinois CancerCare-Peoria, Peoria
Cancer Center of Kansas - Wichita, Wichita
University of Nebraska Medical Center, Omaha
Mayo Clinic in Arizona, Scottsdale
Mayo Clinic in Florida, Jacksonville
New Hampshire Oncology Hematology PA-Hooksett, Hooksett
National Cancer Institute (NCI)
NIH
Academic and Community Cancer Research United
OTHER